Guest guest Posted January 19, 2010 Report Share Posted January 19, 2010 hello group, i just finished reading the latest article sent by chaya venkat of cll topics. the article relates that there is a new study on revlimid (lenolidimide) at roswell park for untreated patients with the worst prognostic factors (11q + 17p deletions), who are untreated and in the early stages of cll. she points out that revlimid works best on patients who have not progressed so far so enough healthy B cells can mount a response--as i understand it the revlimid stimulates the production of the healthy B cells. i am wondering about the aspect of being treated earlier rather than later as we been encouraged to do. i have been advised by two docs to wait as long as possible before treatment, which if i were to begin today, would be the revlimid + rituxin study. my first onc wanted to treat me about 8 months ago. i am now concerned that i may be waiting too long and the revlimid may not be as effective---my hbg is varies from 9.5 - 9.7 so i have significant anemia---wbc is 8k. any comments? best regards, lynn c. no tx, 11q, dx 2006, lymphocytocis since 2001 Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.